A2B adenosine receptor antagonists
Details for Australian Patent Application No. 2002359365 (hide)
International Classifications
Event Publications
3 April 2003 Complete Application Filed
Priority application(s): 60/348,222 09.11.01 US; 60/401,408 05.08.02 US
24 July 2003 Application Open to Public Inspection
Published as AU-B-2002359365
10 July 2008 Application Accepted
Published as AU-B-2002359365
6 November 2008 Standard Patent Sealed
15 October 2009 Amendment Made
The nature of the amendment is: Amend the patentee name from CV Therapeutics, Inc. to Gilead Palo Alto, Inc.
Legal
The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.
Next and Previous Patents/Applications
2002359366-METHOD AND APPARATUS FOR SIDEBAND READ RETURN HEADER IN MEMORY INTERCONNECT
2002359364-POLYMERIC THIOL-LINKED PRODRUGS EMPLOYING BENZYL ELIMINATION SYSTEMS
IP Reporting Samples
Customised IP Reporting
IP Insider for IP Professionals
IP Monitor Professional
- Editable Word format reports
- For IP Professionals
- Multiuser